- Home
- TSHA vs RMNI Comparison
TSHA vs RMNI Comparison
Compare TSHA & RMNI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TSHA
- RMNI
- Stock Information
- Founded
- TSHA 2019
- RMNI 2005
- Country
- TSHA United States
- RMNI United States
- Employees
- TSHA N/A
- RMNI N/A
- Industry
- TSHA Biotechnology: Pharmaceutical Preparations
- RMNI Business Services
- Sector
- TSHA Health Care
- RMNI Consumer Discretionary
- Exchange
- TSHA Nasdaq
- RMNI Nasdaq
- Market Cap
- TSHA 397.8M
- RMNI 368.8M
- IPO Year
- TSHA 2020
- RMNI N/A
- Fundamental
- Price
- TSHA $2.13
- RMNI $3.34
- Analyst Decision
- TSHA Strong Buy
- RMNI Buy
- Analyst Count
- TSHA 8
- RMNI 2
- Target Price
- TSHA $6.63
- RMNI $6.00
- AVG Volume (30 Days)
- TSHA 3.0M
- RMNI 208.1K
- Earning Date
- TSHA 05-16-2025
- RMNI 05-01-2025
- Dividend Yield
- TSHA N/A
- RMNI N/A
- EPS Growth
- TSHA N/A
- RMNI N/A
- EPS
- TSHA N/A
- RMNI N/A
- Revenue
- TSHA $8,333,000.00
- RMNI $426,212,000.00
- Revenue This Year
- TSHA N/A
- RMNI $0.74
- Revenue Next Year
- TSHA N/A
- RMNI $4.46
- P/E Ratio
- TSHA N/A
- RMNI N/A
- Revenue Growth
- TSHA N/A
- RMNI N/A
- 52 Week Low
- TSHA $1.05
- RMNI $1.53
- 52 Week High
- TSHA $4.32
- RMNI $4.15
- Technical
- Relative Strength Index (RSI)
- TSHA 58.69
- RMNI 48.03
- Support Level
- TSHA $1.85
- RMNI $3.22
- Resistance Level
- TSHA $2.28
- RMNI $3.45
- Average True Range (ATR)
- TSHA 0.26
- RMNI 0.21
- MACD
- TSHA 0.03
- RMNI 0.01
- Stochastic Oscillator
- TSHA 52.96
- RMNI 48.00
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.
About RMNI Rimini Street Inc. (DE)
Rimini Street Inc and its subsidiaries are providers of end-to-end enterprise software support, products, and services. The Company offers a comprehensive family of unified solutions to run, manage, support, customize, configure, connect, protect, monitor, and optimize clients' enterprise applications, database, and technology software platforms. The Company derives revenues from clients by providing subscription support services for enterprise resource planning, customer relationship management, product lifecycle management database, and technology software systems. Geographically, the company generates the majority of its revenue from the United States of America and the International market.